{"id":1015425,"date":"2026-10-29T17:54:26","date_gmt":"2026-10-29T21:54:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/"},"modified":"2026-10-29T17:54:26","modified_gmt":"2026-10-29T21:54:26","slug":"pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","title":{"rendered":"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st<\/sup> Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 – 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona.<\/p>\n

\n Poster Presentations<\/strong>\n <\/p>\n

\n Title:<\/strong> Selective targeting of integrins \u03b1v\u03b28 and \u03b1v\u03b21 improves anti-tumor responses mediated by immune checkpoint inhibition<\/p>\n\n\n\n\n\n
\n Poster: <\/strong>\n <\/td>\n615<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nNika Rajabian, Ph.D., Postdoctoral Fellow, National Cancer Institute<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nFriday, November 6, 2026, 12:15 \u2013 1:45 p.m. and 5:30 \u2013 7:30 p.m. Mountain Time<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\nNorth Building – Lower Level – Exhibition Halls 4-6<\/td>\n<\/tr>\n<\/table>\n

*The above presentation includes results that were obtained under a collaboration agreement between the National Cancer Institute and Pliant Therapeutics.<\/p>\n

\n Title:<\/strong> Plasma biomarkers of immune activation predict sensitization to immune checkpoint inhibition (ICI) in patients with advanced solid tumors receiving dual \u03b1v\u03b28\/\u03b1v\u03b21 integrin inhibitor PLN-101095<\/p>\n\n\n\n\n\n
\n Poster<\/strong>\n <\/td>\n546<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nMartin L. Decaris, Ph.D., Vice President, Translational Sciences, Pliant Therapeutics<\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nSaturday, November 7, 2026, 12:00 \u2013 1:30 p.m. and 6:40 \u2013 8:10 p.m. Mountain Time<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\nNorth Building – Lower Level – Exhibition Halls 4-6<\/td>\n<\/tr>\n<\/table>\n

\n
\n
FORTIFY – PLN-101095 Phase 1a\/1b Indication Expansion Trial<\/strong>\n <\/p>\n

PLN-101095 is currently being evaluated in a Phase 1a\/1b open-label, dose-escalation and indication expansion trial (NCT06270706<\/a>) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with\u00a0pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in the Phase 1b trial portion of FORTIFY consisting of three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.<\/p>\n

\n About Pliant Therapeutics, Inc.<\/strong>\n <\/p>\n

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant\u2019s lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of \u03b1v<\/sub>\u00df8<\/sub>\u00a0and \u03b1v<\/sub>\u00df1<\/sub>\u00a0integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1a\/1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant\u2019s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes as well as other cell types.<\/p>\n

For additional information on Pliant, visit\u00a0www.PliantRx.com<\/a> and follow us on\u00a0X<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0Facebook<\/a>.<\/p>\n

\n Investor and Media Contact:<\/strong>
\n
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 – 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona. Poster Presentations Title: Selective targeting of integrins \u03b1v\u03b28 and \u03b1v\u03b21 improves anti-tumor responses mediated by immune checkpoint inhibition Poster: 615 Presenter: Nika Rajabian, Ph.D., Postdoctoral Fellow, National Cancer Institute Date: Friday, November 6, 2026, 12:15 \u2013 1:45 p.m. and 5:30 \u2013 7:30 p.m. Mountain Time Location: North Building – Lower Level – Exhibition Halls 4-6 *The … <\/p>\n

Continue reading “Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015425","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 – 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona. Poster Presentations Title: Selective targeting of integrins \u03b1v\u03b28 and \u03b1v\u03b21 improves anti-tumor responses mediated by immune checkpoint inhibition Poster: 615 Presenter: Nika Rajabian, Ph.D., Postdoctoral Fellow, National Cancer Institute Date: Friday, November 6, 2026, 12:15 \u2013 1:45 p.m. and 5:30 \u2013 7:30 p.m. Mountain Time Location: North Building – Lower Level – Exhibition Halls 4-6 *The … Continue reading "Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-29T21:54:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer\",\"datePublished\":\"2026-10-29T21:54:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\"},\"wordCount\":472,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\",\"name\":\"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=\",\"datePublished\":\"2026-10-29T21:54:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 – 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona. Poster Presentations Title: Selective targeting of integrins \u03b1v\u03b28 and \u03b1v\u03b21 improves anti-tumor responses mediated by immune checkpoint inhibition Poster: 615 Presenter: Nika Rajabian, Ph.D., Postdoctoral Fellow, National Cancer Institute Date: Friday, November 6, 2026, 12:15 \u2013 1:45 p.m. and 5:30 \u2013 7:30 p.m. Mountain Time Location: North Building – Lower Level – Exhibition Halls 4-6 *The … Continue reading \"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-29T21:54:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer","datePublished":"2026-10-29T21:54:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/"},"wordCount":472,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/","name":"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=","datePublished":"2026-10-29T21:54:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjM3MiM3OTI0OTQ1IzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-presentations-at-the-2026-annual-meeting-of-the-society-for-immunotherapy-of-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015425"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015425\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}